MLYS — Mineralys Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension
Mineralys Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Mineralys Therapeutics Inc expected to post a loss of $1.08 a share - Earnings Preview
Brief: Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Brief: Mineralys Therapeutics Announces Mid-Stage Study Of Lorundrostat For Obstructive Sleep Apnea In Patients With Hypertension
Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Mineralys Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension
Brief: Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Mineralys Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Mineralys Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Mineralys Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Mineralys Therapeutics Announces $120 Million Private Placement Financing
Brief: Mineralys Therapeutics Announces First Subject Dosed In Launch-Htn In Trial Of Lorundrostat For Treatment Of Hypertension
Brief: Mineralys Therapeutics Expands Its Board Of Directors With Appointments Of Glenn Sblendorio And Daphne Karydas
Brief: Mineralys Therapeutics Says Target-HTN Successfully Met Its Primary Endpoint
U.S. RESEARCH ROUNDUP-Alteryx, Axsome Therapeutics, Inogen
Brief: Mineralys Therapeutics Announces Expansion Of Planned Phase 2 Trial Of Lorundrostat Alone And In Combination With SGLT2 Inhibitor To Treat Patients With Chronic Kidney Disease